C=o In R Patents (Class 514/621)
-
Publication number: 20110218214Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.Type: ApplicationFiled: September 9, 2010Publication date: September 8, 2011Applicant: ABBOTT LABORATORIESInventors: James T. Link, Qi Shuai, Martin Winn, Hong Yong
-
Publication number: 20110117055Abstract: Provided herein are hepatitis C virus entry inhibitor oxoacetamide compounds, pharmaceutical compositions thereof, and methods for their use in treatment or prevention of hepatitis C virus infection in a subject in need thereof.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Inventors: James E. MacDonald, McKelvy F. Jeffrey, Flossie Wong-Staal
-
Publication number: 20110082109Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: AJINOMOTO CO., INC.Inventors: Wataru MIYANAGA, Yoichiro Shima, Misato Noguchi, Akiko Oonuki, Yayoi Kawato, Hiroshi Iwata, Eri Harada, Ryuta Takashita, Hirokazu Ueno, Tadakiyo Nakagawa
-
Publication number: 20110071142Abstract: The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g.Type: ApplicationFiled: March 19, 2010Publication date: March 24, 2011Applicant: BETH ISRAEL DEACONESS MEDICAL CENTERInventors: Peter Oettgen, Alan C. Rigby, Towia Libermann
-
Publication number: 20110054034Abstract: A method of treating a disease or condition in a warm blooded mammal which disease or condition is suspected to be associated with a microbial infection, comprising: administering an antimicrobial effective amount of a carboxylic acid amide, its isomers or salts thereof, to a subject who is suspected to be infected with a microbe. In one embodiment, the carboxylic acid amide is trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxyphenyl)amide.Type: ApplicationFiled: February 6, 2009Publication date: March 3, 2011Inventors: William Schroeder, JR., Robert P. Smart, Roderick M. Morgan, Arti J. Walker
-
Publication number: 20110020462Abstract: The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal jelly produced thereform. Also provided is a method of promoting the growth of the larva of a queen bee comprising feeding the larva of the queen bee a royal jelly of the invention. Further provided is a method of producing bee larva, pupa and queen bees with sizes larger than normal.Type: ApplicationFiled: July 22, 2009Publication date: January 27, 2011Applicant: NATUREWISE BIOTECH & MEDICALS CORPORATIONInventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jung Chen, Wei-Jan Huang, Li-Ling Chi
-
Publication number: 20100297070Abstract: The invention provides compositions and methods for ameliorating, treating, reversing or preventing pathology or inflammation in the central nervous system (CNS), or the brain, caused or mediated by NFkB, IL-6, IL-6-R, NADPH oxidase (Nox), and/or superoxide and/or hydrogen peroxide production by a NADPH oxidase, including for example ameliorating, treating, reversing or preventing schizophrenia, psychosis, delirium, e.g., post-operative delirium, drug-induced psychosis, psychotic features associated with frailty syndrome (FS), aging, depression, dementias; traumatic war neurosis, post traumatic stress disorder (PTSD) or post-traumatic stress syndrome (PTSS), Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease), and/or Multiple Sclerosis (MS). The invention also provides methods for purifying a C60 fullerene, C3 (tris malonic acid C60) or malonic acid derivatives.Type: ApplicationFiled: October 18, 2008Publication date: November 25, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Laura L. Dugan, Marie Margarita Behrens, Sameh S. Ali
-
Patent number: 7838557Abstract: The present application is directed to the use of X-ray contrast media that act as universal antigens that are labeled herein as “pseudoantigens.” X-ray contrast media have the potential to exist in an aggregated state that is greater in increased concentrations. In this aggregated state, contrast media assume the role of multivalent antigens and can successfully compete with any other antigens involved in antibody-antigen reactions that lead to anaphylaxis. In this competition, the large quantity of contrast media serves to inhibit the adverse effects of antibody-antigen reactions without the contrast media itself creating antibodies or creating toxicity problems.Type: GrantFiled: December 18, 2006Date of Patent: November 23, 2010Assignee: Lasser Family Partnership, L.P.Inventor: Elliott C. Lasser
-
Publication number: 20100292289Abstract: The present invention relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome comprising administering a compound of the invention.Type: ApplicationFiled: November 26, 2008Publication date: November 18, 2010Applicant: AMPLA Pharmaceuticals Inc.Inventor: James R. Hauske
-
Publication number: 20100279963Abstract: Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents.Type: ApplicationFiled: July 1, 2010Publication date: November 4, 2010Applicant: Abraxis BioScience, LLCInventors: Chunlin Tao, Qinwei Wang, Vuong Trieu, Neil Desai, Patrick Soon-Shiong
-
Publication number: 20100240660Abstract: New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.Type: ApplicationFiled: June 1, 2010Publication date: September 23, 2010Applicant: DAC S.R.L.Inventors: Saverio MINUCCI, Pier Giuseppe PELICCI, Antonello MAI, Marco BALLARINI, Gaetano GARGIULO, Silvio MASSA
-
Patent number: 7799954Abstract: Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents.Type: GrantFiled: November 14, 2007Date of Patent: September 21, 2010Assignee: Abraxis BioScience, LLCInventors: Chunlin Tao, Qinwei Wang, Vuong Trieu, Neil Desai, Patrick Soon-Shiong
-
Publication number: 20100234404Abstract: Compounds and compositions for modulating the activity of p38 kinases are provided, including p38?, and p38? kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.Type: ApplicationFiled: May 28, 2010Publication date: September 16, 2010Inventors: Hengyuan Lang, Jiong Lan, Yungeng Fang
-
Patent number: 7767650Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.Type: GrantFiled: June 8, 2006Date of Patent: August 3, 2010Assignee: Galderma Research & DevelopmentInventors: Thibaud Biadatti, Jean-Marie Arlabosse
-
Patent number: 7741352Abstract: This invention relates to novel compounds useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.Type: GrantFiled: March 11, 2004Date of Patent: June 22, 2010Assignee: Neurosearch A/SInventors: William Dalby Brown, Lene Teuber, Bjarne H. Dahl
-
Publication number: 20100120789Abstract: There is provided a compound having Formula I R1—Z—R2 ??Formula I wherein R1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycloalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group R2 is selected from optionally substituted aromatic rings and optionally substituted heterocyclic rings wherein (a) R2 is a 2-substituted thiophene group, and/or (b) Z is a group of the formula —C(?O)—CR3R4—X—(CR5R6)n-, wherein X is selected from NR7, S, O, S?O, and S(?O)2, wherein n is 0 or 1 and/or (c) R1 is an adamantyl group and Z is or comprises an amide group, and/or (d) R1 is an adamantyl group and Z is or comprises a group of the formula —(CR8R9)p- NR10—S(?O)2—(CR11R12)q-, wherein p is 0 or 1 and q is 0 or 1 and/or (e) R1 is an adamantyl group and Z is or comprises a group of the formula —(CR13R14)v-Y—(CR15R16)w- where Y is a heteroaryl group in which a bond in the heteroType: ApplicationFiled: September 7, 2009Publication date: May 13, 2010Inventors: Nigel Vicker, Xiangdong Su, Fabienne Praduax, Michael John Reed, Barry Victor Lloyd Potter
-
Patent number: 7683193Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.Type: GrantFiled: April 4, 2006Date of Patent: March 23, 2010Assignee: University of Southern CaliforniaInventor: Nicos A. Petasis
-
Patent number: 7674829Abstract: The present invention provides methods for treating Acquired Immunodeficiency Syndrome (AIDS) and other viral diseases and Human Immunodeficiency Virus (HIV) related infections by administering one or more compounds of formula I: wherein: the dotted line represents a single or a double bond; and R1 and R2 are the same or different and independently of each other represent —CH2OH, —CH2OR4, —CH(OH)CH3, —CH(OR4)CH3 or a group represented by the formula: or salts or hydrates thereof in a carrier which minimizes micellar formation or van der Waals attraction of molecules of said compound. The invention also provides S enantiomeric forms of such compounds which possess the ability to inhibit cell growth whilst being of low toxicity to such cells and methods of making such compounds.Type: GrantFiled: March 24, 2005Date of Patent: March 9, 2010Assignee: Novaremed LimitedInventor: Eliahu Kaplan
-
Publication number: 20090281154Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.Type: ApplicationFiled: June 7, 2007Publication date: November 12, 2009Inventors: James B. Doherty, Swaminathan R. Natarajan, Dong-Ming Shen, Fengqi Zhang
-
Publication number: 20090270423Abstract: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use.Type: ApplicationFiled: March 27, 2009Publication date: October 29, 2009Inventors: Helen E. Blackwell, Matthew D. Bowman, Joseph R. Stringer
-
Publication number: 20090247522Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.Type: ApplicationFiled: April 22, 2009Publication date: October 1, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Shinji Nara, Hiroshi Nakagawa, Yutaka Kanda, Takayuki Nakashima, Shiro Soga, Jiro Kajita, Jun-ichi Saito, Yukimasa Shiotsu, Shiro Akinaga
-
Publication number: 20090239909Abstract: The present invention relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome comprising administering a compound of the invention.Type: ApplicationFiled: March 24, 2009Publication date: September 24, 2009Applicant: AMPLA Pharmaceuticals Inc.Inventor: James R. Hauske
-
Patent number: 7569725Abstract: Disclosed are anthranilic acid derivatives having Formula (I): and pharmaceutically acceptable salts thereof; and pharmaceutical compositions comprising such compounds. Also disclosed are methods of using such compounds in the treatment of conditions or diseases such as prostate cancer, and methods of using such compounds in the inhibition of 17?-hydroxysteroid dehydrogenase type 3 enzyme.Type: GrantFiled: October 21, 2005Date of Patent: August 4, 2009Assignee: Britsol-Myers Squibb CompanyInventors: Ellen K. Kick, R. Michael Lawrence, Brian E. Fink, Raj N. Misra, Gregory D. Vite
-
Patent number: 7569723Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.Type: GrantFiled: January 15, 2008Date of Patent: August 4, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Jeffrey O'Meara, Christiane Yoakim
-
Publication number: 20090176862Abstract: A method for treating chemo therapy or radiation therapy side effects in a mammal undergoing chemotherapy and/or radiation therapy, the method comprising a step of administering to the mammal a therapeutically effective amount of a RAR antagonist or RAR inverse agonist which binds to receptors of the RAR?, RAR? and RAR? subtypes is disclosed. Such side effects include chemoradiotherapy-induced alopecia, chemoradiotherapy-induced thrombocytopenia, chemoradiotherapy-induced leucopenia and chemoradiotherapy-induced neutropenia.Type: ApplicationFiled: November 13, 2008Publication date: July 9, 2009Applicant: Vitae Pharmaceuticals, Inc.Inventors: Roshantha A. Chandraratna, Yang-Dar Yuan
-
Publication number: 20090163549Abstract: The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene ring or an optionally substituted 6-membered heteroaromatic ring containing N atom, a dashed line means existence or absence of a bond, n is 1 or 2, R1 and R2 are hydrogen etc., R3 is lower alkyl, R4 is lower alkyl or aryloxy, or R3 and R4 taken together may form optionally substituted 5- or 6-membered non-aromatic heterocycle.Type: ApplicationFiled: December 13, 2006Publication date: June 25, 2009Inventor: Hiroyuki Kai
-
Publication number: 20090123512Abstract: Compounds described herein are useful in modulating bacterial quorum sensing.Type: ApplicationFiled: January 20, 2006Publication date: May 14, 2009Inventors: Ute Muh, Brian Hare, Eric Olson, E. Peter Greenberg
-
Publication number: 20090105223Abstract: To provide a novel compound having NMDA receptor channel blocking activity, and also a pharmaceutical agent comprising the compound. A pharmaceutical agent for the treatment or prevention of a disease caused by overexcitation of an NMDA receptor, which comprises a compound having NMDA receptor channel blocking activity and represented by the formula (1), a salt thereof, or a hydrate of the compound or the salt.Type: ApplicationFiled: April 26, 2007Publication date: April 23, 2009Applicant: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Kazuei Igarashi, Hiromitsu Takayama
-
Publication number: 20090075989Abstract: The present invention relates to non-steroidal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.Type: ApplicationFiled: December 20, 2007Publication date: March 19, 2009Inventors: Wolfgang Schwede, Carsten Moeller, Anja Schmidt, Ulrike Fuhrmann, Andrea Rotgeri, Thomas Andrew Kirkland, Ralf Wyrwa
-
Publication number: 20090060873Abstract: The present invention overcomes limitations of the prior art by providing new compounds and methods for the treatment of conditions, such as neurodegenerative diseases (e.g., multiple sclerosis), psychiatric disorders (e.g., psychosis, bipolar disorder, depression, neuropathic pain), conditions involving CNS-mediated chronic pain, spinal cord injuries, and other diseases or injuries.Type: ApplicationFiled: May 5, 2008Publication date: March 5, 2009Applicant: Reata Pharmaceuticals, Inc.Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, John Letterio
-
Publication number: 20090054450Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors.Type: ApplicationFiled: June 17, 2008Publication date: February 26, 2009Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Mark G. CURRIE, John Jeffrey TALLEY, Brian CALI
-
Publication number: 20090048258Abstract: The present invention relate to a compound represented by the formula (I) or (II) wherein ring A is an optionally substituted ring (the ring should not be pyrrolidine, piperidine and piperazine), ring B is an optionally substituted aromatic ring, ring D is an optionally substituted ring, R1 and R2 are each independently a hydrogen atom or a substituent, R3 is a hydrogen atom or a C1-6 alkyl group, or R3 is bonded to ring A to form a non-aromatic ring, ring Aa is an optionally substituted aromatic hydrocarbon, Y is CH or N, Ra1 is an optionally substituted hydrocarbon group, and Ra2 and Ra3 are each independently a hydrogen atom or a substituent, or a salt thereof. The present invention provides a compound having a DGAT inhibitory activity, which is useful for the treatment or amelioration of diseases or pathologies caused by high expression or high activation of DGAT.Type: ApplicationFiled: January 31, 2006Publication date: February 19, 2009Inventors: Masaki Ogino, Yoshihisa Nakada, Mitsuyuki Shimada, Kouhei Asano, Norikazu Tamura, Minori Masago
-
Patent number: 7476763Abstract: Novel cyclohexyl-1,4-diamine compounds corresponding to formula I: methods for their production, pharmaceutical formulations containing these compounds, methods of producing such pharmaceutical formulations and related methods of treating or inhibiting certain diseases or conditions.Type: GrantFiled: November 9, 2006Date of Patent: January 13, 2009Assignee: Gruenenthal GmbHInventors: Corinna Sundermann, Bernd Sundermann
-
Publication number: 20080300314Abstract: Compounds of the formula I give a cooling sensation to the mouth and skin: In Formula I, m is 0 or 1; X is —(CH2)n—R, where n is 0 or 1 and R is selected from —OR?. —COOH, —COOR?, —SO2NH2, —CHO, —COR??, and —CN, R? being selected from H and C1-C3 straight- and branched-chain alkyl. R? from C1-C4 straight- and branched-chain alkyl and R?? from C1-C3 straight- and branched-chain alkyl: Y is selected from H, —COOH and —OR??, where R?? has the significance previously referred to; and Z is H; with the provisos that (iii) When Y is H and X is any of the abovementioned significances, except —CN and —COOH, X is in the 4-position; (iv) when Y has a significance other than H, it is in the 5-position when X is in the 2-position and in the 6-position when X is in the 3-position. The compounds give a cooling sensation that can be more powerful than the best current commercial materials.Type: ApplicationFiled: June 30, 2008Publication date: December 4, 2008Applicant: Givaudan SAInventors: Christophe C. Galopin, Pablo Victor Krawec, Jay Patrick Slack, Lori W. Tigani, Stefan Michael Furrer
-
Publication number: 20080249137Abstract: Compounds are described that are active on at least one of PPAR?, PPAR?, and PPAR?, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR?, PPAR?, and PPAR?.Type: ApplicationFiled: September 6, 2006Publication date: October 9, 2008Inventors: Jack Lin, Patrick Womack, Byunghun Lee, Shenghua Shi, Chao Zhang, Dean R. Artis, Prabha N. Ibrahim, Weiru Wang, Rebecca Zuckerman
-
Publication number: 20080200467Abstract: Disclosed are alpha keto amide and alpha hydroxy amide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.Type: ApplicationFiled: November 2, 2007Publication date: August 21, 2008Inventors: Dinesh Patel, Richard D. Gless, Heather K. Webb Hsu, Sampath Kumar Anandan, Bhaskar R. Aavula
-
Patent number: 7407987Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.Type: GrantFiled: November 30, 2006Date of Patent: August 5, 2008Assignee: Duke UniversityInventors: Mitchell Anthony deLong, John McMillan McIver, Robert Scott Youngquist
-
Publication number: 20080171726Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.Type: ApplicationFiled: August 12, 2007Publication date: July 17, 2008Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
-
Publication number: 20080171725Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.Type: ApplicationFiled: August 10, 2007Publication date: July 17, 2008Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
-
Publication number: 20080146586Abstract: Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents.Type: ApplicationFiled: November 14, 2007Publication date: June 19, 2008Applicant: Abraxis BioScienceInventors: Chunlin Tao, Qinwei Wang, Vuong Trieu, Neil Desai, Patrick Soon-Shiong
-
Patent number: 7388029Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.Type: GrantFiled: May 26, 2005Date of Patent: June 17, 2008Assignee: Duke UniversityInventors: Mitchell Anthony DeLong, John McMillan McIver, Robert Scott Youngquist
-
Patent number: 7378447Abstract: The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptorType: GrantFiled: March 12, 2004Date of Patent: May 27, 2008Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Stephen Andrew Hitchcock, William Wilson Turner, Bin Liu
-
Patent number: 7361653Abstract: The present invention relates to a composition for noxious organisms-controlling agent having a synergistic effect and a method for using said composition, which comprises, as active ingredients thereof, one or more compounds selected from the phthalamide derivatives represented by general formula (I) being useful as an insecticide or acaricide and one or more compounds selected from the compounds having insecticidal, acaricidal or nematocidal activity: wherein R1, R2 and R3 may be the same or different and each represent hydrogen atom, C3-C6 cycloalkyl, -A1-Qp, etc., each of X and Y may be the same or different and represents hydrogen atom, halogen atom, etc., n is an integer of 1 to 4, m is an integer of 1 to 5, and each of Z1 and Z2 represents O or S.Type: GrantFiled: April 16, 2002Date of Patent: April 22, 2008Assignee: Nihon Nohyaku Co., LtdInventors: Kazuyuki Sakata, Masayuki Morimoto, Hiroshi Kodama, Tetsuyosi Nishimatsu
-
Patent number: 7348322Abstract: The present invention relates to compounds of formula I: wherein A, X, R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula I and pharmaceutical compositions comprising the compounds of formula I.Type: GrantFiled: December 8, 2006Date of Patent: March 25, 2008Assignee: Roche Palo Alto LLCInventors: Leyi Gong, Counde O'Yang, Yun-chou Tan
-
Patent number: 7300948Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table R1 R2 R4 R5 R8a F CF3 Me H —OH F CF3 Cl H —OH F CF3 Me H —O—CH2CO2H Cl CN Cl H —OH.Type: GrantFiled: September 29, 2005Date of Patent: November 27, 2007Assignee: Boehringer Ingelheim International GmbHInventors: Pierre Bonneau, Patrick Deroy, Alexandre Gagnon, Jeffrey O′Meara, Bruno Simoneau, Christiane Yoakim
-
Patent number: 7273863Abstract: The present invention includes benzophenone compounds (I) which are useful in the treatment of HIV infections.Type: GrantFiled: August 31, 2000Date of Patent: September 25, 2007Assignee: SmithKline Beecham CorporationInventors: Clarence Webster Andrews, III, Joseph Howing Chan, George Andrew Freeman, Karen Rene Romines, Jeffrey H. Tidwell, Pascal Maurice Charles Pianetti
-
Patent number: 7151117Abstract: The present application is directed to the use of X-ray contrast media that act as universal antigens that are labeled herein as “pseudoantigens.” X-ray contrast media have the potential to exist in an aggregated state that is greater in increased concentrations. In this aggregated state, contrast media assume the role of multivalent antigens and can successfully compete with any other antigens involved in antibody-antigen reactions that lead to anaphylaxis. In this competition, the large quantity of contrast media serves to inhibit the adverse effects of antibody-antigen reactions without the contrast media itself creating antibodies or creating toxicity problems.Type: GrantFiled: September 1, 2005Date of Patent: December 19, 2006Inventor: Elliott C. Lasser
-
Patent number: 7138394Abstract: A vehicle for topical delivery which contains a liquid eutectic mixture of hydrophobic compounds.Type: GrantFiled: September 27, 2002Date of Patent: November 21, 2006Assignee: Alpharx Inc.Inventors: Joseph Schwarz, Michael Weisspapir
-
Patent number: 7129374Abstract: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.Type: GrantFiled: November 26, 2003Date of Patent: October 31, 2006Assignees: Florida Atlantic University, Hospital for Special SurgeryInventors: Herbert Weissbach, Nathan Brot
-
Patent number: RE42700Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis of apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.Type: GrantFiled: July 25, 2008Date of Patent: September 13, 2011Assignees: Sanford-Burnham Medical Research Institute, Oregon State University, SRI International, Molecular Medicine Research Institute, Department of Veterans Affairs, Wayne State UniversityInventors: Marcia Dawson, Joseph A. Fontana, Xiao-Kun Zhang, Mark Leid, Ling Jong, Peter D. Hobbs